Peter Greaney, PhD, joined ADC Therapeutics in September 2018 as Head of Corporate Development.
Dr. Greaney has been responsible for the successful execution of numerous business development deals in his career and has experience in a wide array of deal structures.
Prior to ADC Therapeutics, Dr. Greaney held positions of increasing responsibility at Celgene in Switzerland and the United States. Most recently, he was Director of Business Development, Strategy and Operations, after having served as Associate Director of Business Development. In these roles, Dr. Greaney was responsible for seeking new business opportunities in hematology, oncology, and autoimmune diseases, leading the negotiation teams and managing research collaborations. Dr. Greaney previously held roles in Market Research & Business Intelligence, Medical Affairs, and Medical Development at Celgene. Prior to Celgene, Dr. Greaney was a Preclinical Senior Scientist at Apoxis, S.A. in Switzerland.
Dr. Greaney graduated with a Bachelor of Science (Honors) in Cell Biology from the University of East Anglia and a PhD in Molecular and Cellular Biology from the University of Nottingham.